Kevin joined Quantum in May 2024 as the Head of Advanced Therapies. He brings 25 years of Regulatory Affairs experience in the pharmaceutical, biotech, and medical device industries. Although Kevin has supported clients in a variety of areas, he has significant expertise in vaccines, cell therapy, and gene therapy. In his last several roles, Kevin has led high-performing Regulatory Teams at small to mid-size CROs and boutique consulting firms.